How to use an alexithymia test in clinical practice to improve patient care

Key Takeaways

The alexithymia test is a standardized self-report measure assessing difficulty identifying, describing, and processing emotions.

The most widely used validated instrument is the Toronto Alexithymia Scale (TAS-20), a 20-item questionnaire with three clinical subscales measuring emotional awareness.

Alexithymia screening helps clinicians identify emotion-processing difficulties that underlie anxiety, depression, somatic complaints, and interpersonal conflict.

Pabau’s digital forms enable clinicians to deploy structured intake questionnaires, score results automatically, and integrate findings into patient records for holistic care planning.

Download your free alexithymia test

An alexithymia test helps mental health practitioners identify patients with difficulty recognizing and expressing emotions. This article guides clinicians in deploying alexithymia screening in routine intake workflows, interpreting results, and integrating findings into treatment planning.

What is the alexithymia test?

Alexithymia—literally “without words for emotion”—describes a neuropsychological profile characterized by difficulty identifying feelings, reduced ability to describe emotional states, and an externally focused thinking style. The alexithymia test is a standardized self-report instrument that measures these three dimensions.

The most widely used tool is the Toronto Alexithymia Scale (TAS-20), developed by Bagby, Parker, and Taylor at the University of Toronto. It comprises 20 items rated on a 5-point Likert scale, generating a total score and three subscale scores: Difficulty Identifying Feelings (DIF), Difficulty Describing Feelings (DDF), and Externally Oriented Thinking (EOT).

Alternative validated measures include the Online Alexithymia Questionnaire-G2 (OAQ-G2), a 37-item self-report tool, and the Perth Alexithymia Questionnaire (PAQ), a 24-item measure. Each has distinct psychometric properties and clinical applications.

How to use the test in clinical practice

Deploying an alexithymia test in your practice follows a structured five-step workflow:

1. Introduce during intake. Frame the alexithymia test as part of routine emotional awareness screening. Explain to the patient: “This short questionnaire helps us understand how you process and describe feelings. Your honest answers guide our treatment.”
2. Administer the self-report form. Provide the TAS-20 or equivalent in paper or digital format via digital intake forms that streamline questionnaire collection. Allow 5-10 minutes for completion.
3. Score the responses. Calculate the DIF, DDF, and EOT subscale totals, then sum for an overall score. TAS-20 ranges from 20 (lowest alexithymia) to 100 (highest); scores ≥61 suggest clinically significant alexithymia.
4. Document the result. Record the total score and subscales in the patient record. Highlight elevated subscales (e.g., “DIF elevated, suggests difficulty naming emotions”).
5. Integrate into treatment planning. Use findings to inform psychoeducation, emotion-regulation skill building, and adjunctive therapies like standardized clinical forms for tracking emotional progress.

AI-powered clinical documentation tools accelerate this workflow by auto-scoring questionnaires and generating clinical summaries, reducing manual data entry.

Who benefits from the test?

The alexithymia test benefits clinicians across multiple mental health and medical specialties:

• Therapists and counselors. Assess baseline emotional awareness in clients presenting with depression, anxiety, or relational difficulties. Alexithymia often co-occurs with trauma-related dissociation.
• Psychiatrists and psychiatric nurses. Identify emotion-processing barriers in patients with somatic symptom disorder, panic, or medication-resistant mood conditions.
• Primary care and functional medicine practitioners. Screen for alexithymia in patients with medically unexplained symptoms, chronic pain, or functional GI complaints.
• Occupational therapists and speech-language pathologists. Assess interoceptive awareness deficits in neurodivergent clients (autism, ADHD) for whom emotional identification difficulty impacts social communication.
• Psychiatry EMR software users. Deploy screening as a standardized intake protocol with automated scoring and cross-visit trend tracking.

Benefits of routine screening

Systematic alexithymia screening strengthens clinical outcomes and practice efficiency.

Early identification: Detecting alexithymia traits during intake reveals hidden barriers to therapeutic engagement. Patients with high alexithymia may struggle to report mood shifts or connect emotions to bodily sensations—awareness of this pattern tailors intervention approach.

Personalized treatment. Subscale patterns guide intervention. High DIF (difficulty identifying) warrants emotion-labeling exercises; high DDF (difficulty describing) benefits from narrative therapy or somatic experiencing; high EOT (externally oriented) suggests benefit from mindfulness training.

Objective tracking. Serial alexithymia testing across therapy episodes documents emotional awareness improvement. Patient care workflows integrating structured questionnaires create an auditable record of progress for clinician accountability and burnout prevention.

Compliance and risk reduction. Standardized clinical forms for emotional assessment satisfy documentation requirements for clinical supervision, insurance authorization, and accreditation standards.

Alexithymia and autism: overlapping yet distinct

A common clinical question: Is alexithymia autism? The short answer is no, though the two frequently co-occur.

Alexithymia is a specific difficulty with emotion identification and expression. Autism is a neurodevelopmental condition affecting communication, social interaction, and sensory processing. An autistic person may have typical emotional awareness but express it differently (literal speech, unconventional timing); conversely, a non-autistic person may have profound alexithymia with typical social presentation.

Research suggests alexithymia is more prevalent in autistic adults, possibly because autism involves reduced interoceptive feedback or divergent emotion-processing neurology. Using the alexithymia test in neurodivergent patient engagement strategies clarifies whether emotion-identification difficulty stems from autism, co-occurring alexithymia, or both—shaping support accordingly.

Interpreting the scores

TAS-20 interpretation follows clinical thresholds developed across normative samples:

• 20-51: No significant alexithymia. Patient demonstrates typical emotional awareness and expressiveness.
• 52-60: Borderline alexithymia. Some difficulty naming or describing emotions, but not clinically impaired.
• 61-100: Significant alexithymia. Marked difficulty identifying, describing, or processing emotions warrants psychoeducation and targeted intervention.

Subscale analysis reveals specific deficits. A patient with high DIF but low DDF struggles to identify feelings but can articulate them once named—conversely, high DDF with low DIF shows intact feeling recognition but poor verbal expression. Psychology practice software with integrated scoring dashboards automates this breakdown, surfacing clinically actionable subscale patterns instantly.

Clinical note: The alexithymia test is a screening tool, not a diagnostic instrument. Elevated scores warrant further assessment (clinical interview, standardized measures of emotion regulation, neurodevelopmental screening) before treatment planning.

Conclusion

The alexithymia test is a validated, efficient screening instrument that identifies emotion-processing barriers early in the clinical relationship. By integrating the alexithymia test into routine intake, practitioners gain objective baseline data to personalize interventions, track progress, and optimize therapeutic outcomes. Book a demo to see how Pabau’s digital forms and documentation tools streamline emotion-awareness screening and scoring.

Continue your research

Need a framework for emotion-regulation skill building? Psychiatric evaluation template provides structured assessment domains for documenting emotional and behavioral history alongside alexithymia screening.

Looking to streamline patient intake workflows? Client record features store assessment results, subscale scores, and clinical summaries in a unified patient profile.

Want to automate documentation after assessment? AI-powered scribe tools generate clinical summaries of alexithymia findings and treatment recommendations in seconds.

Frequently asked questions